Anteris Technologies Global CORP. (AVR) — SEC Filings

Overview

Anteris Technologies Global CORP. (AVR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 23, 2026: Anteris Technologies Global Corp. entered into a material definitive agreement on April 23, 2026. The filing is a standard 8-K report, indicating a significant event for the company. Specific details of the agreement are not provided in this summary, but its classification as 'material definitive' s

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bearish, 33 neutral, 2 mixed. The dominant filing sentiment for Anteris Technologies Global CORP. is neutral.

Filing Type Overview

Anteris Technologies Global CORP. (AVR) has filed 27 8-K, 2 S-1, 3 10-Q, 2 DEF 14A, 1 10-K/A, 1 10-K, 1 S-1/A with the SEC between Nov 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• Anteris Technologies Enters Material Definitive Agreement — 8-K · Apr 23, 2026 Risk: medium
  Anteris Technologies Global Corp. entered into a material definitive agreement on April 23, 2026. The filing is a standard 8-K report, indicating a significant
• Anteris Technologies Reports Leadership Changes — 8-K · Dec 15, 2025 Risk: medium
  Anteris Technologies Global Corp. filed an 8-K on December 15, 2025, reporting changes in its board of directors and executive officers, as well as updates to c
• Anteris Technologies Files 8-K on Shareholder Vote — 8-K · Dec 4, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on December 4, 2025, reporting on a submission of matters to a vote of security holders that occurred on December
• 8-K Filing — 8-K · Dec 1, 2025
• Anteris Files S-1 for Resale, Eyes $40.4M from Warrants Amidst Pivotal Trial Launch — S-1 · Nov 26, 2025 Risk: medium
  Anteris Technologies Global Corp. (AVR) filed an S-1 on November 26, 2025, for the resale of up to 9,103,796 shares of common stock by selling stockholders. The
• Anteris Technologies Files 8-K — 8-K · Nov 17, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on November 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, in
• Anteris Technologies Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on November 13, 2025, reporting events as of November 12, 2025. The filing pertains to Results of Operations and
• Anteris's Losses Widen on Soaring R&D, Cash Dwindles — 10-Q · Nov 12, 2025 Risk: high
  Anteris Technologies Global Corp. (AVR) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $65.202 million, up f
• Anteris Seeks Shareholder Nod for Director Elections, Major RSU Grants Post-IPO — DEF 14A · Nov 10, 2025 Risk: medium
  Anteris Technologies Global Corp. (AVR) is holding its 2025 Annual Meeting on December 3, 2025, to address key governance and compensation matters following its
• 8-K Filing — 8-K · Nov 3, 2025
• Anteris Technologies Files 8-K — 8-K · Oct 28, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on October 28, 2025, reporting an event on October 27, 2025. The filing is related to Regulation FD Disclosure an
• Anteris Technologies Files 8-K on Equity Sales — 8-K · Oct 27, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on October 27, 2025, reporting on unregistered sales of equity securities and other events. The filing indicates
• Anteris Technologies Files 8-K on Equity Sales — 8-K · Oct 24, 2025 Risk: medium
  Anteris Technologies Global Corp. filed an 8-K on October 24, 2025, reporting unregistered sales of equity securities and Regulation FD disclosures. The filing
• Anteris Technologies Files 8-K — 8-K · Oct 15, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on October 15, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company,
• Anteris Technologies Files 8-K on Corporate Matters — 8-K · Sep 29, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on September 29, 2025, reporting on matters submitted to a vote of security holders and other events. The filing
• Anteris Technologies Files 8-K — 8-K · Sep 19, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on September 19, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing details the c
• Anteris Technologies Files 8-K — 8-K · Sep 11, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on September 11, 2025, reporting other events and financial statements. The company, incorporated in Delaware, op
• Anteris Technologies Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is
• Anteris Technologies Files Definitive Proxy Statement — DEF 14A · Aug 18, 2025 Risk: low
  Anteris Technologies Global Corp. filed its definitive proxy statement (DEF 14A) on August 18, 2025, for its fiscal year ending December 31, 2025. The filing, w
• Anteris Technologies Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition as of August 11, 2025. The fil
• Anteris Posts Zero Revenue, Deepens Loss Amid DurAVR Trials — 10-Q · Aug 11, 2025 Risk: high
  Anteris Technologies Global Corp. (AVR) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a medical device co
• Anteris Technologies Files 8-K — 8-K · Aug 7, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on August 7, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is inv
• Anteris Technologies Enters Material Definitive Agreement — 8-K · Jul 29, 2025 Risk: medium
  Anteris Technologies Global Corp. filed an 8-K on July 29, 2025, to report the entry into a material definitive agreement. The filing does not disclose specific
• Anteris Technologies Global Corp. Announces Executive & Director Changes — 8-K · Jun 9, 2025 Risk: medium
  Anteris Technologies Global Corp. announced on June 9, 2025, changes in its executive and director positions. The filing details the departure of certain office
• Anteris Technologies Files 8-K on Financials — 8-K · May 14, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on May 14, 2025, reporting events as of May 13, 2025. The filing pertains to Results of Operations and Financial
• Anteris Technologies Global Corp. Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
  Anteris Technologies Global Corp. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware, is involved in the ort
• Anteris Technologies Files 2024 10-K Amendment — 10-K/A · Apr 29, 2025 Risk: low
  Anteris Technologies Global Corp. filed an amendment (10-K/A) on April 29, 2025, for its fiscal year ending December 31, 2024. The company, incorporated in Dela
• Anteris Technologies Files 8-K on March 31, 2025 — 8-K · Mar 31, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on March 31, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation F
• Anteris Technologies Files 8-K — 8-K · Mar 21, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on March 21, 2025, reporting an event that occurred on March 20, 2025. The filing is categorized under Regulation
• Anteris Technologies Files 8-K on Financials — 8-K · Mar 13, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition as of March 10, 2025. The filin
• Anteris Technologies Files 2024 Annual Report — 10-K · Mar 12, 2025 Risk: low
  Anteris Technologies Global Corp. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware, is in
• Anteris Technologies Announces Executive and Director Changes — 8-K · Mar 6, 2025 Risk: medium
  Anteris Technologies Global Corp. announced on March 5, 2025, changes in its executive and director positions. The filing details the departure of certain offic
• Anteris Technologies Files 8-K — 8-K · Jan 15, 2025 Risk: low
  Anteris Technologies Global Corp. filed an 8-K on January 15, 2025, reporting an event on January 14, 2025. The filing is a Regulation FD Disclosure and include
• Anteris Technologies 8-K: Financial Obligation Triggered — 8-K · Dec 19, 2024 Risk: medium
  Anteris Technologies Global Corp. filed an 8-K on December 19, 2024, reporting a triggering event that accelerates or increases a direct financial obligation or
• Anteris Technologies Global Corp. Raises $10M in Private Placement — 8-K · Dec 16, 2024 Risk: medium
  Anteris Technologies Global Corp. announced on December 12, 2024, that it has entered into a securities purchase agreement for a private placement of approximat
• Anteris Technologies Files S-1/A Amendment — S-1/A · Dec 9, 2024 Risk: medium
  Anteris Technologies Global Corp. filed an S-1/A amendment on December 9, 2024, to its registration statement. The company, incorporated in Delaware, is in the
• Anteris Technologies Files S-1 for Securities Registration — S-1 · Nov 22, 2024 Risk: medium
  Anteris Technologies Global Corp. filed an S-1 registration statement on November 22, 2024, to register securities under the Securities Act of 1933. The company

Risk Profile

Risk Assessment: Of AVR's 35 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Anteris Technologies Global CORP.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $1,603,000
• Net Income: -$65,202,000
• EPS: -$1.80
• Debt-to-Equity: N/A
• Cash Position: $9,119,000
• Operating Margin: N/A
• Total Assets: $19,074,000
• Total Debt: N/A

Key Executives

• Wayne Paterson
• John Seaberg
• Gregory Moss
• Stephen Denaro
• David Roberts

Industry Context

Anteris Technologies operates in the rapidly growing structural heart market, specifically focusing on Transcatheter Aortic Valve Replacement (TAVR). This market is characterized by significant innovation and a projected global opportunity of $9.9 billion by 2028. However, it is also highly competitive, with established medical device giants and emerging players vying for market share. Key trends include the shift towards less invasive procedures and the development of next-generation devices with improved durability and patient outcomes.

Top Tags

8-K (8) · disclosure (7) · financial-reporting (7) · financials (5) · 8-k (4) · corporate-governance (4) · sec-filing (4) · Medical Devices (3) · Clinical Trials (3) · operations (3)

Executive Compensation

From the most recent DEF 14A filing (Nov 10, 2025):

• Wayne Paterson — CEO
• John Seaberg — Class I Director
• Gregory Moss — Class I Director
• David Roberts — Director
• Stephen Denaro

Key Numbers

• CIK Number: 0002011514 — Identifier for Anteris Technologies Global Corp.
• Filing Date: 2026-04-23 — Date the 8-K was accepted and filed
• Shares of Common Stock: 9,103,796 — Total shares registered for resale by selling stockholders
• Aggregate gross proceeds: $40.4 million — Potential proceeds to Anteris upon exercise of warrants
• Closing price per share: $3.85 — Closing price of AVR Common Stock on Nasdaq on November 25, 2025
• Patients treated: 130 — Total patients treated with DurAVR THV worldwide as of September 2025
• Net proceeds: $80.0 million — Received from initial public offering on December 12, 2024
• Shares sold in IPO: 14,878,481 — Number of shares sold in the initial public offering at $6.00 per share
• Global market opportunity: $9.9 billion — Projected total global market for TAVR in severe aortic stenosis by 2028
• SEC File Number: 001-42437 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 99-1407174 — Tax identification number for the company.
• Net Loss: $65.202M — Increased from $56.766M in 9M 2024, a 14.86% increase
• R&D Expense: $49.606M — Increased from $38.135M in 9M 2024, a 30.08% increase
• Cash & Equivalents: $9.119M — Decreased from $70.458M at Dec 31, 2024, an 87% decline
• Net Sales: $1.603M — Decreased from $2.167M in 9M 2024, a 26.03% decrease

Related Companies

AVDX · AVTR

Frequently Asked Questions